Achilles Therapeutics plc (ACHL) Financials

ACHL Assets vs Liabilities

DateAssetsLiabilities
Sept. 30, 2023 175.3 million 21.9 million
June 30, 2023 197.9 million 24.1 million
March 31, 2023 207.6 million 22.5 million
Dec. 31, 2022 220.4 million 23.3 million

ACHL Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
Sept. 30, 2023 1.0 million ?
June 30, 2023 -17946 1701
March 31, 2023 -18307 1652
Dec. 31, 2022 -21.8 million 1.7 million

ACHL Net Income

No data available :(

ACHL Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Sept. 30, 2023 140.1 million - 7.4 million
June 30, 2023 143.7 million - 8.6 million
March 31, 2023 158.5 million - 7.6 million
Dec. 31, 2022 173.3 million - 8.6 million

ACHL Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
Sept. 30, 2023 40.1 million
June 30, 2023 39.9 million
March 31, 2023 39.7 million
Dec. 31, 2022 39.3 million

ACHL Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Sept. 30, 2023 61383 14.7 million 4.4 million -
June 30, 2023 537 13.8 million 4.3 million -
March 31, 2023 454 13.9 million 4.7 million -
Dec. 31, 2022 2.1 million 18.9 million 4.0 million -

ACHL Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
Sept. 30, 2023 - 1.2 million
June 30, 2023 - 1.3 million
March 31, 2023 - -
Dec. 31, 2022 - 837227

ACHL

Price: $1.48

52 week price:
0.63
1.49

Earnings Per Share: -1.66 USD

P/E Ratio: -0.83

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United Kingdom

Volume: 354400

Market Capitalization: 56.3 million

Links: